Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story

Simply Wall St.07-16

Syndax Pharmaceuticals (SNDX) put its research pipeline in the spotlight with an R&D event focused on new oncology and fibrosis projects, a development that has drawn fresh attention to the stock. See...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651423242?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-16 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651423242","market":"nz","top_or_hot":-1,"title":"Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story","media":"Simply Wall St.","content":"<div>\n<p>Syndax Pharmaceuticals (SNDX) put its research pipeline in the spotlight with an R&D event focused on new oncology and fibrosis projects, a development that has drawn fresh attention to the stock. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-could-be-40-undervalued-as-pipel\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-16 21:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-could-be-40-undervalued-as-pipel><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Syndax Pharmaceuticals (SNDX) put its research pipeline in the spotlight with an R&D event focused on new oncology and fibrosis projects, a development that has drawn fresh attention to the stock. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-could-be-40-undervalued-as-pipel\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-could-be-40-undervalued-as-pipel","article_id":"2651423242","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-could-be-40-undervalued-as-pipel","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651423242","pubTimestamp":1784209303,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Syndax Pharmaceuticals (SNDX) put its research pipeline in the spotlight with an R&D event focused on new oncology and fibrosis projects, a development that has drawn fresh attention to the stock.\nSee our latest analysis for Syndax Pharmaceuticals.\nThe R&D event comes after a mixed stretch for Syndax Pharmaceuticals, with the share price down 2.53% over the last day and 4.23% over the past week, but showing a 27.27% 1 month share price return and a 1 year total shareholder return of 154.27%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"随着管道更新加剧增长故事，Syndax Pharmaceuticals (SNDX) 的估值可能被低估 40%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1.5},"content_text":"Syndax Pharmaceuticals (SNDX) put its research pipeline in the spotlight with an R&D event focused on new oncology and fibrosis projects, a development that has drawn fresh attention to the stock. See our latest analysis for Syndax Pharmaceuticals. The R&D event comes after a mixed stretch for Syndax Pharmaceuticals, with the share price down 2.53% over the last day and 4.23% over the past week, but showing a 27.27% 1 month share price return and a 1 year total shareholder return of 154.27%. This suggests recent pipeline updates are being weighed against an already strong longer term run. If you are looking beyond Syndax for other healthcare-focused opportunities tied to new therapies and data readouts, this could be a good moment to check out 40 healthcare AI stocks Syndax Pharmaceuticals has already rewarded early believers, but a 1 year total shareholder return above 150% and recent R&D catalysts raise a fresh debate: is most of the upside already priced in, or is the market still behind the story? AdvertisementMost Popular Narrative: 40.5% Undervalued With Syndax Pharmaceuticals last closing at $23.52 against a narrative fair value of $39.50, the current price sits well below what this widely followed framework implies, putting its R&D event into a sharper context.  Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.  Read the complete narrative. Want to understand why this narrative treats Syndax Pharmaceuticals as materially undervalued? It leans on steep revenue expansion, a swing into profitability, and a rich future earnings multiple. Curious which specific assumptions have the most impact on that $39.50 figure, and how sensitive the story is to those inputs? The full narrative lays out the numbers and the tension between ambitious growth and concentrated product risk. Result: Fair Value of $39.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Syndax Pharmaceuticals still faces meaningful risks, including heavy dependence on Revuforj and Niktimvo, as well as uncertainty around upcoming trial results and potential regulatory delays. Find out about the key risks to this Syndax Pharmaceuticals narrative. Next Steps If the Syndax Pharmaceuticals story so far sounds compelling, it could be worth moving quickly to review the numbers and sentiment yourself, then examine the 2 key rewards Looking for more investment ideas beyond Syndax Pharmaceuticals? If Syndax Pharmaceuticals has sharpened your focus, do not stop here. Use the screener tools to quickly surface fresh stocks that fit your style and risk comfort.  Target resilient returns by scanning 78 resilient stocks with low risk scores that aim to hold up when conditions get choppy. Hunt for potential mispriced opportunities using the screener containing 20 high quality undiscovered gems before they sit on everyone else's radar. Prioritise quality and staying power with the solid balance sheet and fundamentals stocks screener (48 results), so you are not caught holding fragile businesses when sentiment turns.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651423242","isCrawlerRequest":true}